Franklin Resources Inc. Decreases Stock Holdings in Twist Bioscience Corporation $TWST

Franklin Resources Inc. lowered its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 20.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 253,442 shares of the company’s stock after selling 65,383 shares during the quarter. Franklin Resources Inc. owned about 0.42% of Twist Bioscience worth $9,324,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Twist Bioscience by 186.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,442,262 shares of the company’s stock valued at $95,883,000 after buying an additional 1,588,587 shares in the last quarter. Strs Ohio acquired a new stake in Twist Bioscience in the first quarter valued at approximately $711,000. Hsbc Holdings PLC purchased a new position in Twist Bioscience in the first quarter worth $228,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Twist Bioscience during the first quarter worth $1,662,000. Finally, Conestoga Capital Advisors LLC acquired a new position in shares of Twist Bioscience during the second quarter worth $1,044,000.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on TWST shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Twist Bioscience in a research report on Wednesday, November 19th. Stephens assumed coverage on Twist Bioscience in a research note on Monday, November 3rd. They issued an “overweight” rating and a $41.00 price target for the company. Evercore ISI lowered their price target on Twist Bioscience from $46.00 to $42.00 and set an “outperform” rating for the company in a report on Tuesday, October 7th. Cowen restated a “buy” rating on shares of Twist Bioscience in a report on Monday, August 4th. Finally, Barclays cut their price objective on shares of Twist Bioscience from $40.00 to $37.00 and set an “overweight” rating on the stock in a report on Monday, November 17th. Nine analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.33.

Twist Bioscience Stock Up 0.6%

Shares of TWST stock opened at $31.88 on Friday. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $55.33. The firm has a market capitalization of $1.95 billion, a PE ratio of -24.33 and a beta of 2.43. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.33 and a current ratio of 3.64. The stock’s 50-day simple moving average is $30.26 and its 200-day simple moving average is $30.94.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Friday, November 14th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($0.05). Twist Bioscience had a negative net margin of 20.63% and a negative return on equity of 27.40%. Twist Bioscience has set its Q1 2026 guidance at EPS. FY 2026 guidance at EPS. Equities analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, SVP Paula Green sold 1,084 shares of the company’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $32.08, for a total value of $34,774.72. Following the sale, the senior vice president directly owned 142,187 shares of the company’s stock, valued at $4,561,358.96. This represents a 0.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dennis Cho sold 1,019 shares of the firm’s stock in a transaction on Monday, November 3rd. The stock was sold at an average price of $32.08, for a total transaction of $32,689.52. Following the transaction, the insider directly owned 120,694 shares of the company’s stock, valued at approximately $3,871,863.52. This trade represents a 0.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 122,865 shares of company stock worth $3,879,926. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.